Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | PLAT | P00750 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 6/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351945 | 1.00 | PLG (0.50) | PLGPLATLMNAEPHX2NCF1 | |
| SCHEMBL5523332 | 1.00 | PLG (0.50) | PLGPLATLMNAEPHX2NCF1 | |
| Hydrochloric Acid SCHEMBL7415651 | 0.97 | PLG (0.48) | PLGPLATLMNAEPHX2NCF1 | |
| Hydrochloric Acid SCHEMBL7415656 | 0.97 | PLG (0.48) | PLGPLATLMNAEPHX2NCF1 | |
| Monoethanolamine SCHEMBL10958862 | 0.92 | PLG (0.44) | PLGPLATLMNAEPHX2NCF1 | |
| Hydrazine SCHEMBL1873192 | 0.83 | ESR1 (0.42) | PLGPLATLMNAEPHX2ESR1 | |
| SCHEMBL1703765 | 0.83 | PLG (0.55) | PLGPLATLMNAEPHX2NCF1 | |
| SCHEMBL48375 | 0.83 | PLG (0.55) | PLGPLATLMNAEPHX2NCF1 | |
| SCHEMBL6802 | 0.83 | — | — | |
| SCHEMBL432248 | 0.83 | PLG (0.55) | PLGPLATLMNAEPHX2NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4673726-A | Poly(ester-imides) and poly(ester-imide-amides) of trimellitic anhydride and 4-(aminomethyl)cyclohexanemethanol | EASTMAN KODAK COMPANY (US) | 1987-06-16 | — | — | US | claimed |
| US-4645802-A | MOLDING MATERIALS | EASTMAN KODAK COMPANY (US) | 1987-02-24 | — | — | US | claimed |
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260034107-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS | VTV THERAPEUTICS LLC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260027090-A1 | Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity | VTV THERAPEUTICS LLC (US) | 2026-01-29 | — | — | US | disclosed |
| WO-2024233846-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC | 2023-10-05 | — | — | US | disclosed |
| US-11649230-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230127944-A1 | BROAD-SPECTRUM CARBAPENEMS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-04-27 | — | — | US | disclosed |
| US-20230127944-A1 | BROAD-SPECTRUM CARBAPENEMS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-04-27 | — | — | US | disclosed |
| US-20230093476-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING REFRACTIVE OCULAR DISORDERS | VTV THERAPEUTICS LLC | 2023-03-23 | — | — | US | disclosed |
| WO-2004105755-A1 | BENZOTHIAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES RELATED TO THE ADENOSINE A2A RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-09 | — | — | WO | disclosed |
| US-20040242576-A1 | Urea substituted benzothiazoles | HOFFMANN-LA ROCHE INC. | 2004-12-02 | — | — | US | disclosed |
| EP-0450066-B1 | CARBOSTYRIL DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 1996-09-11 | — | — | EP | disclosed |
| US-5401740-A | FOR INHIBITING PLATELET AGGREGATION | OTSUKA PHARMACEUTICAL CO. (JP) | 1995-03-28 | — | — | US | disclosed |
| US-5227381-A | Anticoagulant | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-13 | — | — | US | disclosed |
| EP-0450066-A1 | CARBOSTYRIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-10-09 | — | — | EP | disclosed |
| US-4769441-A | Poly(ester-imide-amide of trimellitic anhydride, 4-(aminomethyl)cyclohexanemethanol and aromatic dicarboxylic acid | EASTMAN KODAK COMPANY (US) | 1988-09-06 | — | — | US | disclosed |
| US-4673726-A | Poly(ester-imides) and poly(ester-imide-amides) of trimellitic anhydride and 4-(aminomethyl)cyclohexanemethanol | EASTMAN KODAK COMPANY (US) | 1987-06-16 | — | — | US | disclosed |
| US-4645802-A | MOLDING MATERIALS | EASTMAN KODAK COMPANY (US) | 1987-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | GLS, HMOX2, REN | PLG 305/4885PLAT 972/4885LMNA 3422/4885 |
| US-11649230-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | PLG 246/4885PLAT 1132/4885LMNA 2765/4885 |
| US-20260027090-A1 | Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity | CSF1R, CD209, NFATC1 | PLG 1278/4885PLAT 1167/4885LMNA 3672/4885 |
| US-20230127944-A1 | BROAD-SPECTRUM CARBAPENEMS | MGAM, ALPI, SI | PLG 1419/4885PLAT 1800/4885LMNA 1640/4885 |
| US-20230093476-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING REFRACTIVE OCULAR DISORDERS | ALDH1A2, UACA, PDE6D | PLG 2064/4885PLAT 3371/4885LMNA 2297/4885 |
| US-20260034107-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS | HBB, HBZ, HBG1 | PLG 4543/4885PLAT 3802/4885LMNA 973/4885 |
| US-20040242576-A1 | Urea substituted benzothiazoles | UTS2R, ADRB2, TBXA2R | PLG 4580/4885PLAT 4433/4885LMNA 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.